Regeneron stock slips on a $85.2 billion market value

Published on 09/06/2026 at 15:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron stock trades with a market value of USD 85.218 billion as of September 6, 2026.

Fotorealistisches Biotech-Labor mit Forschern und Pipetten an sterilen Arbeitsplätzen — Regeneron Pharma US75886F1075 zeigt ein fotorealistisches Biotech-Labor mit Forschern bei sorgfältigen Pipettierarbeiten am sterilen Steriltisch, Illustration mit AI erstellt.

Regeneron Pharmaceuticals, Inc. (US75886F1075) trades at USD 827.72, with a market capitalization of USD 85.218 billion and a daily move of -1.87 percent as of September 6, 2026. On the same market snapshot, the stock also shows up with an industry label of biotechnology.

Stock value and peer context

The available market snapshot places Regeneron alongside Vertex Pharmaceuticals, which is listed at USD 546.12 and a market value of USD 138.42 billion. The comparison is straightforward: Regeneron is smaller in size, but still a large-cap biotech name, and the gap between USD 85.218 billion and USD 138.42 billion is material for investor positioning.

Regeneron is not a broad-market story here. The key numbers are the USD 827.72 quote, the USD 85.218 billion valuation, and the -1.87 percent move, all visible in the same current market data set for September 6, 2026.

Biotech scale matters

For a company in biotechnology, market capitalization can matter as much as the latest headline. Here, the number is large enough to keep Regeneron in the top tier of U.S. health care stocks, even without stretching beyond the figures that are actually visible in the current market snapshot.

The comparison with Vertex gives the most concrete read-through: Vertex is at USD 546.12 and USD 138.42 billion, while Regeneron stands at USD 827.72 and USD 85.218 billion. That puts the focus on relative scale rather than on a short-term narrative.

Go deeper

More on Regeneron Pharmaceuticals

Track the latest company context, market data, and investor material around Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals overview

Regeneron drugs and pipeline

Regeneron is best known for its antibody and specialty medicine portfolio, which keeps the company tied to pricing, launch execution, and prescription trends rather than to a single product cycle. That business model is what makes a market-cap snapshot useful even on a thin news day.

Price and market cap

Regeneron stock trades at USD 827.72 as of September 6, 2026, with a market capitalization of USD 85.218 billion and a daily change of -1.87 percent. The same snapshot shows the share as a large biotechnology name in the U.S. market.